ViiV Healthcare Technology Transfer & ARV Licensing

Partnership objectives

  1. Expand and accelerate access to HIV treatment for those in need.
  2. Support and build technical capacity in communities in which ViiV works.

ViiV Healthcare provides a royalty-free licence for the development, manufacture and supply of paediatric medicines where 99% of all children with HIV live. ViiV Healthcare provides a royalty-free licence for the development, manufacture and supply of paediatric medicines where 99% of all children with HIV live. Copyright GSK

Description of partnership activities and how they address needs and challenges

GlaxoSmithKline granted its first voluntary licence in 2001. Now under the auspices of ViiV Healthcare, the number of licences has been extended to sixteen royalty free licencing agreements for ViiV Healthcare's ARVs to all least developed countries, all low income countries and sub-Saharan Africa.

ViiV Healthcare's licencees supplied 1.1 billion tablets of their versions of Epivir® and Combivir® to Africa in 2012.

In 2014 ViiV Healthcare granted two voluntary licences to the Medicines Patent Pool in order to expand access to their newest medicine dolutegravir, just three months after its approval by the European Medicines Agency (EMA), This agreement included a royalty-free voluntary licence for manufacture and supply of dolutegravir in all low-income, all least-developed and all sub-Saharan African countries – covering over 93% of all adults living with HIV. Additionally, ViiV Healthcare also provided a royalty-freee licence for the development, manufacture and supply of paediatric formulations of dolutegravir in the countries where 99% of all children with HIV live.

Because ViiV Healthcare understands that price is not the only barrier to access, ViiV Healthcare is committed to developing meaningful partnerships with communities, academic institutions and NGOs that focus on areas where ViiV Healthcare’s expertise can make the most difference – leveraging its core business activities, skills and resources in order to build and support local capacity through sustainable and appropriate investments.


At ViiV Healthcare We Are All Connected To HIV

Partnership information

Company(ies) GlaxoSmithKline , Pfizer , Shionogi

Partner(s) Apotex, Medicines Patent Pool, ViiV Healthcare

Type of Partner(s) Generic Manufacturers, NGOs, Other Business

Therapeutic Focus Women and Children's Health, Infectious Diseases

Disease(s) Children's Health, HIV/AIDS

Program Type(s) Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Research & Development - Development of Treatments, Research & Development - Operations Research, Research & Development - Pediatric R&D

Targeted Population(s) Children, Men, Mothers, Patients in needs of treatment, People with low income, Women

Region(s) Sub-Saharan Africa

Number of Countries 48

Country(ies) Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Zambia, Zimbabwe

Start Date 2001

More information ViiV Healthcare

Anticipated completion date Ongoing